Phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)

RECORD-4 prospectively assessed second-line everolimus after initial VEGF-targeted therapy or cytokines in mRCC (N=134), Overall population (N=134), median PFS was 7.8 months (95% CI, 5.7-11.0) and median OS was 23.8 months (95% CI, 17.0-NE), Safety population (n=133), median duration of exposure was 5.8 months; 56% of patients experienced grade 3/4 AEs, regardless of study drug relationship, Results confirm the clinical benefit of second-line everolimus

from Cancer via ola Kala on Inoreader http://ift.tt/1IdxnZN
via IFTTT